Jula Inrig Sells 1,018 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 1,018 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $42.61, for a total value of $43,376.98. Following the transaction, the insider directly owned 111,473 shares in the company, valued at approximately $4,749,864.53. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total value of $302,524.95.
• On Wednesday, February 4th, Jula Inrig sold 1,779 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.21, for a total value of $57,301.59.
• On Tuesday, February 3rd, Jula Inrig sold 6,956 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total value of $223,426.72.

Travere Therapeutics Stock Performance

TVTX traded down $1.18 during midday trading on Wednesday, hitting $40.95. 4,521,912 shares of the company traded hands, compared to its average volume of 2,203,580. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $3.78 billion, a PE ratio of -136.50 and a beta of 0.86. The company’s 50-day moving average is $29.57 and its 200 day moving average is $31.37. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $43.31.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TVTX. Piper Sandler upgraded shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price objective on the stock in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. decreased their target price on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, March 25th. Guggenheim increased their price target on Travere Therapeutics from $49.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TVTX. Raymond James Financial Inc. purchased a new stake in Travere Therapeutics in the 2nd quarter worth approximately $33,000. First Horizon Corp purchased a new position in Travere Therapeutics during the third quarter valued at approximately $36,000. State of Wyoming bought a new position in shares of Travere Therapeutics in the fourth quarter worth approximately $37,000. Torren Management LLC bought a new position in shares of Travere Therapeutics in the fourth quarter worth approximately $38,000. Finally, Comerica Bank increased its stake in shares of Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after purchasing an additional 492 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.